Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Cwm LLC

Cwm LLC increased its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 42.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,796 shares of the biopharmaceutical company’s stock after acquiring an additional 2,014 shares during the period. Cwm LLC’s holdings in Royalty Pharma were worth $191,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of RPRX. Xponance Inc. grew its position in Royalty Pharma by 38.8% in the third quarter. Xponance Inc. now owns 18,218 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 5,090 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Royalty Pharma by 75.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 209,576 shares of the biopharmaceutical company’s stock worth $5,612,000 after purchasing an additional 90,282 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Royalty Pharma by 103.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock valued at $2,171,000 after purchasing an additional 40,582 shares during the last quarter. Inspire Investing LLC purchased a new stake in shares of Royalty Pharma during the third quarter valued at $364,000. Finally, TD Asset Management Inc boosted its position in shares of Royalty Pharma by 49.4% in the 3rd quarter. TD Asset Management Inc now owns 290,483 shares of the biopharmaceutical company’s stock valued at $7,884,000 after purchasing an additional 96,026 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on RPRX. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Thursday, April 11th. Bank of America reduced their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, April 12th. The Goldman Sachs Group lowered their price objective on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 20th. Finally, JPMorgan Chase & Co. reduced their target price on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and an average price target of $46.75.

Royalty Pharma Stock Performance

Shares of RPRX opened at $28.41 on Friday. The company’s 50 day moving average price is $29.36 and its 200 day moving average price is $28.58. The company has a debt-to-equity ratio of 0.61, a quick ratio of 7.90 and a current ratio of 7.90. Royalty Pharma plc has a 52 week low of $25.92 and a 52 week high of $35.70. The company has a market capitalization of $16.97 billion, a PE ratio of 15.03 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.12. The business had revenue of $736.00 million during the quarter, compared to analyst estimates of $702.90 million. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. Research analysts expect that Royalty Pharma plc will post 3.95 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 17th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date of this dividend is Thursday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 44.44%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.